

## References for the Medical History Interest Group presentation

### “The History and Current State of Publication Bias and Inadequate Trial Transparency in the Health Sciences”

About AllTrials. AllTrials website. <http://www.alltrials.net/find-out-more/about-alltrials/>.

Accessed/link last verified December 3, 2014.

Adams B. The pioneers of transparency. *BMJ*. 2015;350:g7717. doi: 10.1136/bmj.g7717.

Ahmed I, Sutton AJ, Riley RD. Assessment of publication bias, selection bias, and unavailable data in meta-analyses using individual participant data: a database survey. *BMJ*. 2012;344:d7762.

Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? *JAMA*. 2003;290(7):921-928.

Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. *JAMA*. 2003;289(4):454-465.

Bhandari M, Busse JW, Jackowski D, et al. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. *CMAJ*. 2004;170(4):477-480.

*BMJ*. 2012 Jan 7;344(7838).

*BMJ*. 2012 Nov 3;345(7881).

Bourgeois FT, Murthy S, Mandl KD. Outcome reporting among drug trials registered in ClinicalTrials.gov. *Ann Intern Med*. 2010 Aug 3;153(3):158-66.

Buchkowsky SS, Jewesson PJ. Industry sponsorship and authorship of clinical trials over 20 years. *Ann Pharmacother*. 2004;38(4):579-585.

Castellani J. Are clinical trial data shared sufficiently today? Yes. *BMJ*. 2013;347:f1881.

Chalmers I, Glasziou P, Godlee F. All trials must be registered and the results published: academics and non-commercial funders are just as guilty as industry. *BMJ*. 2013;346:f105.

Chalmers I, Vallance P. Secure use of individual patient data from clinical trials. *Lancet*. 2013 Sept 28;382:1073-1074.

Chalmers I. Proposal to outlaw the term “negative trial”. *BMJ*. 1985 March 30;290:1002.

Chalmers I. Underreporting research is scientific misconduct. *JAMA*. 1990 Mar 9;263(10):1405-1408.

Chan A. Out of sight but not out of mind: how to search for unpublished clinical trial evidence. *BMJ*. 2012;344:d8013.

Chan AW, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. *JAMA*. 2004 May 26;291(20):2457-2465.

Cohen D. Complications tracking down the data on oseltamivir. *BMJ*. 2009 Dec 12;339:b5387.

Cohen D. Rosiglitazone: what went wrong? *BMJ*. 2010 September 6;341:c4848. doi: <http://dx.doi.org/10.1136/bmj.c4848>.

Committee on Finance, United States Senate with Max Baucus, Chairman and Chuck Grassley, Ranking Member. Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia. <http://www.finance.senate.gov/newsroom/chairman/download/?id=9e4b091f-de21-4df1-b65e-b227d74bec12>. January 2010. Accessed/link last verified August 15, 2014.

Committee on Finance, United States Senate. Staff Report to the Chairman and Ranking Member. The Intimidation of Dr. John Buse and the Diabetes Drug Avandia. <http://www.finance.senate.gov/download/?id=883E903D-F973-4A74-8432-3C651C71B4B4>. November 2007. Accessed/link last verified August 15, 2014.

Cowley AJ, Skene A, Stainer K, Hampton JR. The effect of lorainide on arrhythmias and survival in patients with acute myocardial infarction: an example of publication bias. *Int J Cardiol*. 1993;40:161-166.

De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. International Committee of Medical Journal Editors. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. *N Engl J Med*. 2004 Sep 16;351(12):1250-1251. Epub 2004 Sep 8.

De Angelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. International Committee of Medical Journal Editors. Is this clinical trial fully registered?--A statement from the International Committee of Medical Journal Editors. *N Engl J Med*. 2005 Jun 9;352(23):2436-2438. Epub 2005 May 23.

Department of Justice, Office of Public Affairs. GlaxoSmithKline to plead guilty and pay \$3 billion to resolve fraud allegations and failure to report safety data. 2012 Jul 2. <http://www.justice.gov/opa/pr/glaxosmithkline-plead-guilty-and-pay-3-billion-resolve-fraud-allegations-and-failure-report>. Accessed/link last verified December 13, 2014.

Dickersin K, Chalmers I. Recognising, investigating and dealing with incomplete and biased reporting of clinical research: from Francis Bacon to the World Health Organisation. James Lind Library, 2010. (Available at: <http://www.jameslindlibrary.org/illustrating/articles/recognising-investigating-and-dealing-with-incomplete-and-biase>).

Dickersin K. Publication bias: recognizing the problem, understanding its origins and scope, and preventing harm. In: Rothstein HR, Sutton AJ, and Borenstein M, eds. *Publication Bias in Meta-Analysis: Prevention, Assessment and Adjustments*. West Sussex, England: John Wiley & Sons; 2005:11-33.

Djulbegovic B, Lacey M, Cantor A, et al. The uncertainty principle and industry-sponsored research. *Lancet* 2000;356(9230):635-638.

Doody RS, Raman R, Farlow M, et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. *N Engl J Med*. 2013 July 25;369(4):341-350.

Doshi P, Dickersin K, Healy D, Vedula SS, Jefferson T. Restoring invisible and abandoned trials: a call for people to publish the findings. *BMJ*. 2013 Jun 13;346:f2865. doi: 10.1136/bmj.f2865.

Doshi P, Jefferson T, Del Mar C. The imperative to share clinical study reports: recommendations from the Tamiflu experience. *PLoS Med*. 2012;9(4): e1001201. doi: 10.1371/journal.pmed.1001201.

Doshi P. Neuraminidase inhibitors: the story behind the Cochrane review. *BMJ*. 2009 Dec 12; 339:b5164.

Doshi P. Putting GlaxoSmithKline to the test over paroxetine. *BMJ*. 2013;347:f6754. doi: 10.1136/bmj.f6754.

Drazen JM, Morrissey S, Curfman GD. Rosiglitazone--continued uncertainty about safety. *N Engl J Med*. 2007 Jul 5;357(1):63-64. Epub 2007 Jun 5.

Dwan K, Altman DG, Cresswell L, Blundell M, Gamble CL, Williamson PR. Comparison of protocols and registry entries to published reports for randomised controlled trials. *Cochrane Database Syst Rev*. 2011 Jan 19;(1):MR000031. doi: 10.1002/14651858.MR000031.pub2.

Dwan K, Gamble C, Williamson PR, Kirkham JL, for the Reporting Bias Group. Systematic review of the empirical evidence of study publication bias and outcome reporting bias – an updated review. *PLoS ONE*. July 2013;8(7): e66844,1-37. doi:10.1371/journal.pone.0066844

Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. *N Engl J Med*. 1991 Mar 21;324(12):781-788.

Editorial commentary. Dealing with biased reporting of the available evidence. 2007. The James Lind Library ([www.jameslindlibrary.org](http://www.jameslindlibrary.org)).

Editorial. The reporting of unsuccessful cases. *Boston Medical and Surgical Journal*. 1909;161:263-264.

Eikelboom JW, Connolly SJ, Brueckmann, M, Granger CB, Kappetein AP, Mack MJ, et al. Dabigatran versus warfarin in patients with mechanical heart valves. *N Engl J Med*. 2013 Sept 26;369(13):1206-1214.

European Medicines Agency. European Medicines Agency policy on publication of clinical data for medicinal products for human use. October 2, 2014.

[www.ema.europa.eu/docs/en\\_GB/document\\_library/Other/2014/10/WC500174796.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Other/2014/10/WC500174796.pdf).

Accessed/link last verified January 1, 2015.

Evans I, Thornton H, Chalmers I, Glasziou P. *Testing Treatments: Better Research for Better Healthcare*. 2nd ed. London: Pinter & Martin Ltd, 2011. (Also available online: [www.testingtreatments.org](http://www.testingtreatments.org)).

FDA Amendments Act of 2007. <http://www.gpo.gov/fdsys/pkg/PLAW-110publ85/pdf/PLAW-110publ85.pdf>. [In particular, see pages 82 (<http://www.gpo.gov/fdsys/pkg/PLAW-110publ85/pdf/PLAW-110publ85.pdf#page=82>), 91 (<http://www.gpo.gov/fdsys/pkg/PLAW-110publ85/pdf/PLAW-110publ85.pdf#page=91>), and 98 (<http://www.gpo.gov/fdsys/pkg/PLAW-110publ85/pdf/PLAW-110publ85.pdf#page=98>), with the areas referenced therein and pages between also being recommended.]

FDAAA 801 requirements. ClinicalTrials.gov website. <https://www.clinicaltrials.gov/ct2/manage-recs/fdaaa>. Last reviewed December 2014. Accessed/link last verified December 19, 2014.

Ferriar J. *Medical Histories and Reflexions*, vol 1. London: Cadell and Davies, 1792. (In particular, see the preface; available in full at <https://play.google.com/books/reader?printsec=frontcover&output=reader&id=wG0FAAAAQAAJ&pg=GBS.PP7>)

Furberg CD. Effect of antiarrhythmic drugs on mortality after myocardial infarction. *American Journal of Cardiology*. 1983;52:32C-36C.

Giel JL. Comparison of results reporting on ClinicalTrials.gov by funding source. *Curr Med Res Opin*. 2011;27(Suppl 1):S8. doi:10.1185/03007995.2011.564047 (only available in an abstract format due to it being from a presentation at the Annual Meeting of the International Society for Medical Publication Professionals).

Godlee F, Clarke M. Why don't we have all the evidence on oseltamivir? *BMJ*. 2009 Dec 12;339:b5351.

Godlee F. One promise fulfilled, much still to be done. *BMJ*. 2015;350:g7811. doi: 10.1136/bmj.g7811.

Godlee F. We want raw data, now. *BMJ*. 2009;339:b5405.

Goldacre B. Are clinical trial data shared sufficiently today? No. *BMJ*. 2013;347:f1880.

Goldkind L. Medical officer's gastroenterology advisory committee briefing document. [http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1\\_05\\_gi.pdf](http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_05_gi.pdf). Accessed/link last verified August 24, 2011.

Guyatt G, Rennie D, Meade MO, Cook DJ, eds. *Users' guides to the medical literature: Essentials of evidence-based clinical practice*. 2nd ed. American Medical Association, 2008.

Harris G. Diabetes drug maker hid test data, files indicate. *The New York Times*. 2010 July 13. <http://www.nytimes.com/2010/07/13/health/policy/13avandia.html>. Accessed/link last verified December 13, 2014. (Avandia and its risks. <http://documents.nytimes.com/avandia-and-its-risks>. Accessed/link last verified December 13, 2014. [This is a linked supplemental document for the Harris G article on Avandia. Page numbers are based on consecutive physical page count due to inconsistent/no pagination in the file.]

Hart B, Lundh A, Bero L. Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses. *BMJ*. 2012;344:d7202.

Hawkes N. Industry and drug regulators disagree on which data should remain confidential. *BMJ*. 2013;347:f5390 doi: 10.1136/bmj.f5390.

Hawkes N. Lifetime achievement award 2014: Sir Iain Chalmers. *BMJ*. 2014;348:g2921. doi: 10.1136/bmj.g2921.

Heneghan CJ, Onakpoya I, Thompson M, Spencer EA, Jones M, Jefferson T. Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. *BMJ*. 2014 Apr 9;348:g2547. doi: 10.1136/bmj.g2547.

Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, et al. Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. *N Engl J Med*. 2007 Jul 5;357(1):28-38. Epub 2007 Jun 5.

Hopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K. Publication bias in clinical trials due to statistical significance or direction of trial results. *Cochrane Database Syst Rev*. 2009;4. Accession # 00075320-100000000-05507.

Hrachovec J, Mora M. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. *JAMA*. 2001;286(19):2398-2400.

Huser V, Cimino JJ. Linking ClinicalTrials.gov and PubMed to track results of interventional human clinical trials. *PLoS ONE*. 2013 July 9;8(7):e68409.

Institute of Medicine (IOM). 2015. *Sharing clinical trial data: Maximizing benefits, minimizing risk*. Washington, DC: The National Academies Press

Jefferson T, Doshi P, Thompson M, Heneghan C. Ensuring safe and effective drugs: who can do what it takes? *BMJ*. 2011 Jan 15;342:c7258.

Jefferson T, Jones M, Doshi P, Del Mar C, Dooley L, Foxlee R. Neuraminidase inhibitors for preventing and treating influenza in healthy adults. *Cochrane Database Syst Rev*. 2010;2: CD001265. doi: 10.1002/14651858.CD001265.pub3.

Jefferson T, Jones M, Doshi P, Del Mar C. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. *BMJ*. 2009 Dec 8;339:b5106. doi: 10.1136/bmj.b5106.

Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. *BMJ*. 2014 Apr 9;348:g2545. doi: 10.1136/bmj.g2545.

Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. *Cochrane Database Syst Rev*. 2014;4:CD008965. doi: 10.1002/14651858.CD008965.pub4.

Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, et al. 2014. Data from: Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Dryad Digital Repository. <http://dx.doi.org/10.5061/dryad.77471>. Accessed/link last verified November 20, 2014.

Jefferson T, Jones MA, Doshi P, Del Mar CB, Heneghan CJ, Hama R, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. *Cochrane Database Syst Rev*. 2013;6:CD008965. doi: 10.1002/14651858.CD008965.pub3

Jefferson TO, Demicheli V, Di Pietrantonj C, Jones M, Rivetti D. Neuraminidase inhibitors for preventing and treating influenza in healthy adults. *Cochrane Database Syst Rev.* 2006;3:CD001265. doi: 10.1002/14651858.CD001265.pub2.

Jones CW, Handler L, Crowell KE, Keil LG, Weaver MA, Platts-Mills TF. Non-publication of large randomized clinical trials: cross sectional analysis. *BMJ.* 2013;347:f6104.

Jones CW, Platts-Mills TF. Quality of registration for clinical trials published in emergency medicine journals. *Ann Emerg Med.* 2012 Oct;60(4):458-464.e1. doi: 10.1016/j.annemergmed.2012.02.005. Epub 2012 Apr 14.

Jüni P, Rutjes AW, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? *BMJ.* 2002;324:1287–1288.

Jureidini JN, Nardo JM. Inadequacy of remote desktop interface for independent reanalysis of data from drug trials. *BMJ.* 2014 Jul 9;349:g4353. doi: 10.1136/bmj.g4353.

Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. *Arch Intern Med.* 2003;163:1667-1672.

Killeen S, Souralious P, Hunter IA, Hartley JE, Grady HL. Registration rates, adequacy of registration, and a comparison of registered and published primary outcomes in randomized controlled trials published in surgery journals. *Ann Surg.* 2014 Jan;259(1):193-196. doi: 10.1097/SLA.0b013e318299d00b.

Kirilova O. Results and outcome reporting in ClinicalTrials.gov, what makes it happen? *PLoS ONE.* 2012;7(6):e37847. doi:10.1371/journal.pone.0037847

Law MR, Kawasumi Y, Morgan SG. Despite law, fewer than one in eight completed studies of drugs and biologics are reported on time on ClinicalTrials.gov. *Health Aff (Millwood).* 2011 Dec;30(12):2338-45. doi:10.1377/hlthaff.2011.0172.

Lehman R, Loder E. Missing clinical trial data: a threat to the integrity of evidence based medicine. *BMJ.* 2012;344:d8158.

Loder E, Tovey D, Godlee F. The Tamiflu trials. *BMJ.* 2014 Apr 9;348:g2630. doi: 10.1136/bmj.g2630.

Lu HL. Statistical reviewer briefing document for the advisory committee. [www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1\\_04\\_stats.doc](http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_04_stats.doc). Accessed/link last verified August 24, 2011.

Mahaffey KW, Hafley G, Dickerson S, Burns S, Tourt-Uhlig S, White J, et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. *Am Heart J.* 2013 Aug;166(2):240-249.e1. doi: 10.1016/j.ahj.2013.05.004. Epub 2013 Jun 5.

Mathieu S, Boutron I, Moher D, Altman DG, Ravaud P. Comparison of registered and published primary outcomes in randomized controlled trials. *JAMA.* 2009 Sep 2;302(9):977-84. doi: 10.1001/jama.2009.1242.

Mathieu S, Chan A-W, Ravaud P. Use of trial register information during the peer review process. *PLoS ONE*. 2013;8(4):e59910. doi:10.1371/journal.pone.0059910.

Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B. Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. *BMJ*. 2003 May 31;326(7400):1171-1173.

Moore TJ. *Deadly Medicine: Why Tens of Thousands of Patients Died in America's Worst Drug Disaster*. New York, NY: Simon & Schuster; 1995.

Moynihhan R. Rosiglitazone, marketing, and medical science. *BMJ*. 2010;340:c1848.

Nathan DM. Rosiglitazone and cardiotoxicity — weighing the evidence. *N Engl J Med*. 2007 Jul 5;357(1):64-66. Epub 2007 Jun 5.

NIH. Clinical trials registration and results submission. 2014 Nov 21.

<http://www.regulations.gov#!documentDetail;D=NIH-2011-0003-0003>.

[<http://www.regulations.gov/contentStreamer?objectId=090000648193bc18&disposition=attachment&contentType=pdf>]. Accessed/link last verified December 18, 2014.

NIH. HHS and NIH take steps to enhance transparency of clinical trial results. 2014 Nov 19.

<http://www.nih.gov/news/health/nov2014/od-19.htm>. Accessed/link last verified December 18, 2014.

NIH. Key changes proposed in the NPRM. 2014 Nov 19.

<http://www.regulations.gov#!documentDetail;D=NIH-2011-0003-0001>.

[<http://www.regulations.gov/contentStreamer?objectId=090000648193837a&disposition=attachment&contentType=pdf>] Accessed/link last verified December 18, 2014.

NIH. NPRM at a glance. 2014 Nov 21. <http://www.regulations.gov#!documentDetail;D=NIH-2011-0003-0002>.

[<http://www.regulations.gov/contentStreamer?objectId=090000648193837b&disposition=attachment&contentType=pdf>] Accessed/link last verified December 18, 2014.

NIH. Summary of HHS/NIH proposals to enhance transparency of clinical trial results. 2014 Nov 19.

[http://www.nih.gov/news/health/nov2014/od-19\\_summary.htm](http://www.nih.gov/news/health/nov2014/od-19_summary.htm). Accessed/link last verified December 18, 2014.

Nisen P, Rockhold F. Access to patient-level data from GlaxoSmithKline clinical trials. *N Engl J Med*. 2013 Aug 1;369:475-478.

Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. *N Engl J Med*. 2007 June 14;356(24):2457-2471. doi: 10.1056/NEJMoa072761.

Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. *Arch Intern Med*. 2010 Jul 26;170(14):1191-1201. doi: 10.1001/archinternmed.2010.207.

Nissen SE. Setting the RECORD straight. *JAMA*. 2010 March 24/31;303(12):1194-1195.



Open Data campaign. *The BMJ* website. <http://www.bmj.com/open-data>. Accessed/link last verified December 20, 2014.

Payne D. Tamiflu: the battle for secret drug data. *BMJ*. 2012;345:e7303.

Petticrew, M. Diagoras of Melos (500 BC): An early analyst of publication bias. *Lancet*. 1998 Nov 7;352(9139):1558.

Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. *N Engl J Med*. 2014 Apr 10;370(15):1383-1392. doi: 10.1056/NEJMoa1313731.

Prayle AP, Hurley MN, Smyth AR. Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study. *BMJ*. 2012 Jan 3;344:d7373.

Psaty BM, Furberg CD. The record on rosiglitazone and the risk of myocardial infarction. *N Engl J Med*. 2007 July 5;357(1):67-69. doi: 10.1056/NEJMe078116.

Ross JS, Mulvey GK, Hines EM, Nissen SE, Krumholz HM. Trial publication after registration in ClinicalTrials.gov: a cross-sectional analysis. *PLoS Med*. 2009 Sep;6(9):e1000144. doi: 10.1371/journal.pmed.1000144. Epub 2009 Sep 8.

Ross JS, Tse T, Zarin DA, Xu H, Zhou L, Krumholz HM. Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis. *BMJ*. 2012;344:d7292.

Sackett DL, Rosenberg WMC, Gray JAM, Haynes RB, Richardson WS. Evidence based medicine: What it is and what it isn't. *BMJ*. 1996; 312:71-72.

Sample I. Big pharma mobilising patients in battle over drugs trials data. *Guardian*. 2013 July 21.

Scargle JD. Publication bias: the 'file drawer' problem in scientific inference. *J Sci Exploration*. 2000;14(1):91-106.

Silverman WA. *Where's the evidence?* Oxford: Oxford University Press, 1998.

Silverstein F, Simon L, Faich G. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. In reply. *JAMA*. 2001;286(19):2399-2400.

Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. *JAMA*. 2000;284(10):1247-1255.

Smith J, on behalf of Roche. Point-by-point response from Roche to *BMJ* questions. *BMJ*. 2009 Dec 12;339:b5374.

Smith J, on behalf of Roche. Roche replies to the authors of the Cochrane review on oseltamivir. *BMJ*. 2009 Dec 12;339:b5364.

Song F, Parekh S, Hooper L, Loke YK, Ryder J, Sutton AJ, et al. Dissemination and publication of research findings: an updated review of related biases. *Health Technol Assess*. 2010;14(8):iii-xi,1-193.



Sterling T. Publication decisions and their possible effects on inferences drawn from tests of significance -- Or vice versa. *J Am Stat Assoc.* 1959 March;54(285):30-34.

Sterling TD, Rosenbaum WL, Weinkam JJ. Publication decisions revisited: the effect of the outcome of statistical tests on the decision to publish and vice versa. *Am Stat.* 1995 Feb;49(1):108-112.

Strom BL, Buyse M, Hughes J, Knoppers BM. Data sharing, year 1--access to data from industry-sponsored clinical trials. *N Engl J Med.* 2014 Nov 27;371(22):2052-4. doi: 10.1056/NEJMp1411794. Epub 2014 Oct 15. (See also the online disclosures document associated with this perspective piece.)

Supporters. AllTrials website. <http://www.alltrials.net/supporters/organisations/>. Accessed/link last verified January 3, 2015.

Tamiflu campaign. *The BMJ* website. <http://www.bmj.com/tamiflu>. Accessed/link last verified December 20, 2014.

Tamiflu timeline. *The BMJ* website. <http://embed.verite.co/timeline/?source=0Aq8WxSy6z4gAdFV6anBySFppYWNZOtBZHRDTUoxb1E&font=Bevan-PotanoSans&maptype=toner&lang=en&height=650>. Accessed/link last verified December 23, 2014.

Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: an overview of results from randomized controlled trials. *JAMA.* 1993 Oct 6;270(13):1589-1595.

The Cardiac Arrhythmia Suppression Trial-II Investigators. Effect of antiarrhythmic agent moricizine on survival after myocardial infarction: the Cardiac Arrhythmia Suppression Trial-II. *N Engl J Med.* 1992 July 23;327:227-233.

Thomas K. In documents on pain drug Celebrex, signs of doubt and deception. *New York Times.* 2012 June 24. <http://www.nytimes.com/2012/06/25/health/in-documents-on-pain-drug-celebrex-signs-of-doubt-and-deception.html>. Accessed/link last verified September 27, 2013. (Combating doubts about Celebrex. <http://www.nytimes.com/interactive/2012/06/25/health/25celebrex-document.html>. Accessed/link last verified September 27, 2013. [This is a linked supplemental document for the Thomas K article on Celebrex. Page numbers are based on consecutive physical page count due to inconsistent/no pagination in the file.]

Treasure T, Monson K, Fiorentino F, Russell C. The CEA Second-Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer. *BMJ Open.* 2014 May 13;4(5):e004385. doi: 10.1136/bmjopen-2013-004385.

Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. *N Engl J Med.* 2008 Jan 17;358(3):252-260.

U.S. National Institutes of Health. ClinicalTrials.gov background. <https://clinicaltrials.gov/ct2/about-site/background>. Accessed/link last verified August 25, 2014.

Vedula SS, Bero L, Scherer RW, Dickersin K. Outcome reporting in industry-sponsored trials of gabapentin for off-label use. *N Engl J Med.* 2009 Nov 12;361(20):1963-1971.

Vedula SS, Goldman PS, Rona IJ, Greene TM, Dickersin K. Implementation of a publication strategy in the context of reporting biases. A case study based on new documents from Neurontin<sup>®</sup> litigation. *Trials*. 2012;13(136):1-13. [Also: Additional file for Vedula et al. *Trials* 2012;13(136):1-45.]

Vedula SS, Li T, Dickersin K. Differences in reporting of analyses in internal company documents versus published trial reports: comparisons in industry-sponsored trials in off-label uses of gabapentin. *PLoS Med*. 2013 Jan;10(1):e1001378. doi:10.1371/journal.pmed.1001378.

Walster GW, Cleary TA. A Proposal for a New Editorial Policy in the Social Sciences. *Am Stat*. 1970 Apr;24(2):16-19

What does all trials registered and reported mean? AllTrials website. <http://www.alltrials.net/find-out-more/all-trials/>. Accessed/link last verified December 3, 2014.

Wieland LS, Robinson KA, Dickersin K. Understanding why evidence from randomised clinical trials may not be retrieved from Medline: comparison of indexed and non-indexed records. *BMJ*. 2011;344:d7501.

Wieseler B, Wolfram N, McGauran N, Kerekes MF, Vervölgyi V, Kohlepp P, et al. Completeness of reporting of patient-relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available data. *PLoS Med*. 2013 Oct;10(10):e1001526. doi: 10.1371/journal.pmed.1001526. Epub 2013 Oct 8.

Witter J. Celebrex capsules (celecoxib), NDA 20-998/S-009, medical officer review. [www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1\\_03\\_med.pdf](http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_03_med.pdf). Accessed/link last verified August 24, 2011.

World Medical Association. *Declaration of Helsinki: ethical principles for medical research involving human subjects*. 2008 October. Available at: <http://www.wma.net/en/30publications/10policies/b3/17c.pdf>. Accessed/link last verified August 6, 2014.

Wright JM, Perry TL, Bassett KL, Chambers KG. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. *JAMA*. 2001;286(19):2398-2399.

Zarin DA. Participant-level data and the new frontier in trial transparency. *N Engl J Med*. 2013 Aug 1;369(5):468-469.